A New Multi-Billion-Dollar Healthcare Revolution is Already Here

The AI healthcare market is set to grow from $11 billion in 2021 to $187 billion by 2030.

All thanks to demand and use for AI in diagnostics, genomics, precision medicine, pharmaceutical research and the global digital health market.

Artificial Intelligence is Fueling a Massive Opportunity in Healthcare

A number of fast-growing companies appear poised for substantial growth as a result of this opportunity.

Look at Bio-Techne Corporation (NASDAQ: TECH), for example.

The company just launched a new suite of AI-designed innovative recombinant proteins, which are designed to address critical needs in cellular therapy workflows and research applications, including improved cell culture performance and optimized cell expansion.

BioNTech (NASDAQ: BNTX) is integrating advanced artificial intelligence to revolutionize individualized medicine. In fact, with its in-house AI specialist, InstaDeep, it is using AI to develop personalized vaccines and targeted therapies, as noted in a press release.

Recursion Pharmaceuticals (NASDAQ: RXRX), a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery, is helping to accelerate drug discovery, shorten the development process, reduce costs and identify more effective treatments with AI.

In fact, Recursion just announced the open-source release of Boltz-2, a biomolecular foundation model developed in collaboration with MIT researchers. It’s expected to significantly help improve the accuracy and speed of drug discovery processes.

Avantor (NYSE: AVTR) is integrating artificial intelligence to strengthen laboratory efficiency, streamline research and development, and optimize supply chain management. These AI-driven initiatives are central to Avantor’s vision of creating the “Lab of the Future.”

Another company poised to seize this opportunity, while flying below the radar, is PanGenomic Health (CSE: NARA).

PanGenomic Health is developing an intelligent, AI-powered wellness ecosystem designed to help users take control of their physical and mental well-being with precision treatments rooted in natural medicine, genomics and diagnostic insights.

In fact, the company’s Nara.ai platform is allowing users to leverage artificial intelligence to help them achieve personal well-being, and help them treat specific ailments on their own.

Nara is a mental health app that curates natural remedies for individuals to manage and improve their mental wellness. With personalized insights and evidence-backed resources, users can take back control of their mental health.

The Nara.AI platform will leverage the NARA app and Mujn diagnostic tools to make recommendation information available for the user or their health practitioner about personalized alternative health treatments, including initial dosages and dose changes from ongoing monitoring.

It’s essentially putting a personal health coach in your back pocket.

Driving further interest, the threshold for taking supplements is breaking down – especially with

Robert F. Kennedy Jr.’s “Make America Healthy Again” movement.

We also have to consider that fewer and fewer Americans can actually afford sky-high treatment costs – another key reason millions of Americans are interested in supplements.

Again, that’s substantial news for companies, like PanGenomic Health, which has positioned itself to be a valuable wellness resource for consumers while monetizing multiple parts of the consumer’s wellness journey:

• E-commerce: PanGenomic Health’s largest future revenue stream will come from its AI-powered product recommendation engine. As users shop for supplements, peptides and wellness solutions, PanGenomic receives a portion of every transaction.
• App Subscriptions: Users pay to unlock advanced tools inside the NARA app, such as ongoing tracking, deeper insights and premium guidance.
• Diagnostic Tools: Through MUJN, PanGenomic Health will generate revenue by offering subscription and per-use pricing on its biomarker tracking hits.

With a market cap of just roughly $2 million CAD, PanGenomic is also trading at a valuation well below its peers, while offering significant upside potential for investors.